RxDoctor Payments Data

Yvette Sisk, NP

Family · Winston Salem, NCNPI 1427008820

Payments from drug & device makers

$590in general payments, 2019–2025

Across 16 payments — averaging $36.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$107
  • Daiichi Sankyo Inc.$75
  • Incyte Corporation$75
  • Seagen Inc.$70
  • AVEO Pharmaceuticals, Inc.$67
  • Novartis$39
  • plus $157 from 6 others

What the payments were for

  • Food & beverage$26345%
  • Education$32755%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$590 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$26,661
Medicare patients
208
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$532,389
PomalystPomalidomide21$473,117
IbrancePalbociclib11$174,986
Abiraterone Acetate24$112,834
EliquisApixaban48$31,639
XareltoRivaroxaban17$13,339
AranespDarbepoetin Alfa In Polysorbat12$8,731
Letrozole67$2,138
Ondansetron OdtOndansetron35$1,051
Hydroxyurea60$891
Oxycodone Hcl69$849
Anastrozole43$772
Tamoxifen Citrate14$479
Ondansetron Hcl46$478
Acyclovir43$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$28$473,11721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →